Core Viewpoint - Shanghai Xuerong Biological Technology Co., Ltd. has announced the early redemption of its convertible bonds, "Xuerong Convertible Bonds," due to the triggering of conditional redemption clauses based on stock price performance [1][2]. Group 1: Convertible Bond Redemption Announcement - The company will redeem "Xuerong Convertible Bonds" at a price of 100.93 CNY per bond, which includes accrued interest [1][8]. - The redemption is triggered as the company's stock price has been above 120% of the conversion price for 15 trading days within the specified period [2][7]. - The redemption will be completed by October 15, 2025, and the bonds will be delisted from the Shenzhen Stock Exchange thereafter [1][9]. Group 2: Convertible Bond Details - The company issued 5,850,000 convertible bonds on June 24, 2020, with a total fundraising amount of 585 million CNY [2][3]. - The conversion period for the bonds started on January 4, 2021, and will end on June 23, 2026 [3]. - The conversion price has been adjusted multiple times, with the latest adjustment setting it at 4.10 CNY per share effective from August 26, 2024 [6][7]. Group 3: Redemption Process - The redemption will be executed for all bondholders registered with China Securities Depository and Clearing Corporation Limited by the close of trading on October 14, 2025 [8][9]. - The accrued interest for the bonds is calculated based on a formula that considers the principal amount, interest rate, and the number of days since the last interest payment [8][7]. - Bondholders are advised to consult their brokerage firms regarding the conversion process before the redemption [9][10].

Group 1 - The core announcement is that Xuerong Biological will forcibly redeem its convertible bonds ("Xuerong Convertible Bonds") if they are not converted by the close of trading on October 14, 2025 [2] - Following the redemption, the "Xuerong Convertible Bonds" will be delisted from the Shenzhen Stock Exchange [2] - Bondholders are advised to convert their bonds before the deadline and to resolve any pledges or freezes on their bonds to avoid being forced to redeem them [2]

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 2、赎回条件满足日：2025 年 9 月 3 日 3、停止交易日：2025 年 10 月 10 日 4、赎回登记日：2025 年 10 月 14 日 5、赎回日：2025 年 10 月 15 日 上海雪榕生物科技股份有限公司 关于提前赎回雪榕转债的第一次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"雪榕转债"赎回价格：100.93 元/张（含当期应计利息，当期年利率为 3.00%，且当期利息含税），扣税后的赎回价格以中国证券登记结算有限责任公 司深圳分公司（以下简称"中国结算"）核准的价格为准。 6、停止转股日：2025 年 10 月 15 日 12、债券持有人若转股，需开通创业板交易权限。投资者不符合创业板股票 适当性管理要求的，不能将所持"雪榕转债"转换为股票，特提请投资者关注不 能转股的风险。 13、风险提示：根据安排，截至 2025 年 ...

Group 1 - The board of directors of Shanghai Xuerong Biological Technology Co., Ltd. has decided to exercise the early redemption rights of the "Xuerong Convertible Bonds" due to the stock price exceeding 120% of the conversion price for 15 consecutive trading days [1][2] - The conversion price of the bonds is set at 4.92 yuan per share, which has been surpassed by the stock price during the specified period [1] - The resolution to redeem the bonds was passed with 7 votes in favor, 0 against, and 0 abstentions [2] Group 2 - The company will authorize its management and relevant departments to handle all matters related to the redemption of the "Xuerong Convertible Bonds" [2] - The announcement regarding the early redemption will be published on the designated information disclosure website of the China Securities Regulatory Commission [2]

（文章来源：证券日报） 证券日报网讯 9月3日晚间，雪榕生物发布公告称，根据安排，截至2025年10月14日收市后仍未转股 的"雪榕转债"将被强制赎回，本次赎回完成后，"雪榕转债"将在深圳证券交易所摘牌。特提醒"雪榕转 债"持有人注意在限期内转股。债券持有人持有的"雪榕转债"如存在被质押或被冻结的，建议在停止转 股日前解除质押或冻结，以免出现因无法转股而被赎回的情形。 ...

Group 1 - The company, Xuerong Biological, announced the approval of the proposal for the early redemption of "Xuerong Convertible Bonds" during the 32nd meeting of its fifth board of directors [2]

Core Viewpoint - The company, Shanghai Xuerong Biotechnology Co., Ltd., has announced the early redemption of its convertible bonds, "Xuerong Convertible Bonds," due to the triggering of conditional redemption clauses based on stock price performance [1][2]. Group 1: Convertible Bond Redemption Announcement - The company will redeem "Xuerong Convertible Bonds" at a price of 100.93 CNY per bond, and after the redemption, the bonds will be delisted from the Shenzhen Stock Exchange [1][2]. - Bondholders are advised to convert their bonds into shares before the redemption deadline to avoid potential losses due to forced redemption [1][2]. - The redemption was approved by the company's board on September 3, 2025, after the stock price met the required conditions [2][3]. Group 2: Convertible Bond Issuance and Terms - The company issued 5,850,000 convertible bonds on June 24, 2020, with a total fundraising amount of 585 million CNY [2][3]. - The bonds were listed on the Shenzhen Stock Exchange on July 24, 2020, under the code "123056" [3]. - The conversion period for the bonds is from January 4, 2021, to June 23, 2026 [3]. Group 3: Conditional Redemption Clauses - The conditional redemption clause allows the company to redeem the bonds if the stock price exceeds 120% of the conversion price for at least 15 trading days within a 30-day period [6][7]. - The redemption conditions were met between August 14, 2025, and September 3, 2025, triggering the redemption process [7][8]. Group 4: Redemption Price Calculation - The redemption price of 100.93 CNY per bond includes the principal and accrued interest calculated based on a 3% annual interest rate for 113 days [8][9]. - The accrued interest for each bond is calculated to be 0.93 CNY, leading to the total redemption price [8][9]. Group 5: Redemption Process and Timeline - The redemption will be executed on October 15, 2025, with funds transferred to bondholders' accounts by October 22, 2025 [9][10]. - The company will notify bondholders of the redemption details and the delisting of the bonds [9].

Core Viewpoint - The legal opinion letter from Grandall Law Firm confirms that Shanghai Xuerong Biotechnology Co., Ltd. has met the necessary legal requirements for the early redemption of its convertible bonds, known as "Xuerong Convertible Bonds" [4][14]. Group 1: Company Background and Bond Issuance - The company issued a total of 585 million yuan in convertible bonds, which were approved by the China Securities Regulatory Commission (CSRC) and listed on the Shenzhen Stock Exchange on July 24, 2020 [9][10]. - The bonds have a term of six years and were issued under the approval number CSRC License [2020] 634 [9]. Group 2: Redemption Conditions - The company has the right to redeem the bonds if the stock price exceeds 120% of the conversion price for at least 15 trading days within a 30-day period or if the remaining balance of the bonds is less than 30 million yuan [10][13]. - The conversion price has been adjusted multiple times, with the latest adjustment setting it at 4.10 yuan per share, effective from August 26, 2024 [12]. Group 3: Approval and Compliance - The board of directors approved the early redemption of the bonds on September 3, 2025, based on the stock price performance and market conditions [13][14]. - The company is required to fulfill its information disclosure obligations as per the relevant regulations following the redemption [14].

雪榕生物公告，公司控股股东杨勇萍先生及其一致行动人浙江银万私募基金管理有限公司-银万华奕1号 私募证券投资基金持股比例由21.1404%下降至20.8842%，因公司可转债转股，公司总股本增加，导致 持股比例被动稀释。本次权益变动不涉及控股股东及其一致行动人减持公司股份。 ...

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 关于控股股东及其一致行动人持股比例变动触及1%刻度的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本次权益变动基本情况 本次权益变动前，上海雪榕生物科技股份有限公司（以下简称"公司"）控股股 东杨勇萍先生及其一致行动人浙江银万私募基金管理有限公司-银万华奕1号私募证 券投资基金（以下简称"银万华奕1号"）合计持有公司股份126,341,450股，占公司股 份总数的21.1404%。因公司可转债转股，公司总股本增加，导致杨勇萍先生及其一 致行动人持股比例被动稀释。截至2025年9月2日，杨勇萍先生及其一致行动人持股 数量未发生变化，持股比例由上述的21.1404%下降为20.8842%。 本次权益变动不涉及控股股东及其一致行动人减持公司股份。现将具体情况公 告如下： | 1.基本情况 | | | | | | | | | | | | ...